BTX BioTime, Inc. Common Stock

2.97
+0  (0%)
Previous Close 2.97
Open 3.04
Price To book 2.56
Market Cap 305.23M
Shares 102,772,000
Volume 348,477
Short Ratio 20.98
Av. Daily Volume 288,734

SEC filingsSee all SEC filings

  1. 8-K - Current report 17623241
  2. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 17622242
  3. 8-K - Current report 17614749
  4. 8-K - Current report 17595391
  5. 424B5 - Prospectus [Rule 424(b)(5)] 17594793

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 six and nine-month data released January 24, 2017 from AIS-A 10 million-cell cohort. 12-month efficacy and safety data for this cohort, as well as 6-month efficacy and safety data for the currently-enrolling AIS-A 20 million cell and AIS-B 10 million cell cohorts, due 3Q 2017.
AST-OPC1 - SCiStar
Cervical spinal cord injury
Pivotal trial data due by mid-2017.
Renevia
Restoring normal skin contours in for patients with HIV
Phase 2 second cohort underway. Data due early 2017.
OpRegen
Dry age-related macular degeneration (AMD)
Phase 2b planned for 2018.
AST-VAC1
Maintenance of relapse-free-survival in acute myeloid leukemia (AML)

Latest News

  1. 6:46 am BioTime announced the deconsolidation of OncoCyte Inc.'s financial statements from its statements effective February 17; co will report a pro forma, non-cash gain of approx. $56 mln
  2. BioTime Reports Pro Forma Gain on Deconsolidation of OncoCyte Subsidiary
  3. BIOTIME INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits
  4. BIOTIME INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  5. BioTime, Inc. Announces Closing of Public Offering of Common Stock
  6. CORRECTING and REPLACING BioTime Expands Ophthalmology Portfolio With Global In-Licensing Agreement for Next-Generation Retinal Disease Therapy From University of Pittsburgh
  7. BioTime to Present at Two Upcoming Investor Conferences
  8. BIOTIME INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
  9. BioTime Declares $17.5M Public Stock Offering
  10. BioTime, Inc. Announces Pricing of Public Offering of Common Stock
  11. BIOTIME INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  12. BioTime, Inc. Announces Proposed Public Offering of Common Stock
  13. Acorda, Amgen and Regeneron Lead Premarket Biotech Movers
  14. BioTime Appoints Industry Veteran, Stephana Patton, Ph.D., J.D., as General Counsel
  15. BioTime Expands Ophthalmology Portfolio With Global In-Licensing Agreement for Next-Generation Retinal Disease Therapy From University of Pittsburgh Medical Center
  16. LifeSci Capital Initiates Coverage of BioTime, Inc.
  17. BioTime to Present at Noble Capital Markets’ Thirteenth Annual Investor Conference
  18. Additional Data From BioTime’s OpRegen® Clinical Trial in Dry-AMD to be Presented at ARVO 2017
  19. BioTime, Inc. breached its 50 day moving average in a Bearish Manner : BTX-US : January 12, 2017
  20. BioTime and Subsidiary Cell Cure Neurosciences Establish Innovative Cell Therapy Manufacturing Center in Jerusalem, Israel

SEC Filings

  1. 8-K - Current report 17623241
  2. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 17622242
  3. 8-K - Current report 17614749
  4. 8-K - Current report 17595391
  5. 424B5 - Prospectus [Rule 424(b)(5)] 17594793
  6. 8-K - Current report 17587711
  7. 424B5 - Prospectus [Rule 424(b)(5)] 17587684
  8. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 17521094
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 161975570
  10. 8-K - Current report 161972112